ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Bruce J. Leavitt
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fellinger, E. K.
Right arrow Articles by Hebert, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fellinger, E. K.
Right arrow Articles by Hebert, J. C.
Related Collections
Right arrow Extracorporeal circulation

Ann Thorac Surg 2002;74:1187-1190
© 2002 The Society of Thoracic Surgeons

Original article: cardiovascular

Serum levels of prophylactic cefazolin during cardiopulmonary bypass surgery

Erika K. Fellinger, MDa, Bruce J. Leavitt, MDa*, James C. Hebert, MD, FACSa

a Department of Surgery, University of Vermont College of Medicine, Burlington, Vermont, USA

Accepted for publication March 18, 2002.

* Address reprint requests to Dr Leavitt, University of Vermont, Fletcher House 4, 111 Colchester Ave, Burlington VT 05401, USA.
e-mail: bruce.leavitt{at}vtmednet.org

BACKGROUND: Controversy exists regarding the appropriate prophylactic dose of cefazolin for coronary artery bypass grafting (CABG) surgery requiring cardiopulmonary bypass (CPB) because the effect of CPB on serum drug levels is poorly understood. Current standards of prophylaxis are based primarily on empiric studies. Few studies have attempted to quantify serum cefazolin levels in either cardiac or noncardiac surgeries. This study was conducted to measure and assess the adequacy of the intraoperative serum levels of prophylactic cefazolin in CPB surgery.

METHODS: This prospective study serially measured six intraoperative serum cefazolin levels in 10 subjects undergoing elective and urgent CABG surgery. We compared the serum levels with the minimum inhibitory concentrations (MIC90) for the most common organisms causing postoperative infection.

RESULTS: Serum-free cefazolin levels fluctuated considerably during the operation but remained above the MIC90 for Staphylococcus aureus and S. epidermidis. The serum levels fell below the MIC90 for Enterobacter, Serratia, Escherichia coli, and Proteus mirabilis.

CONCLUSIONS: Serum cefazolin levels during CPB remained consistently above the MIC for two of the three main organisms causing postoperative infection but were suboptimal for the remainder. Additional studies are needed to assess the intraoperative serum levels of single-dose cefazolin prophylaxis and to explore alternate dosing methods that minimize intraoperative fluctuations in serum cefazolin levels.




This article has been cited by other articles:


Home page
 Ann. Thorac. Surg.Home page
D. Hutschala, K. Skhirtladze, C. Kinstner, B. Mayer-Helm, M. Muller, E. Wolner, and E. M. Tschernko
In Vivo Microdialysis to Measure Antibiotic Penetration Into Soft Tissue During Cardiac Surgery
Ann. Thorac. Surg., November 1, 2007; 84(5): 1605 - 1610.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
R. Engelman, D. Shahian, R. Shemin, T. S. Guy, D. Bratzler, F. Edwards, M. Jacobs, H. Fernando, and C. Bridges
The Society of Thoracic Surgeons Practice Guideline Series: Antibiotic Prophylaxis in Cardiac Surgery, Part II: Antibiotic Choice
Ann. Thorac. Surg., April 1, 2007; 83(4): 1569 - 1576.
[Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
A. D. Caffarelli, J. P. Holden, E. J. Baron, H. J.M. Lemmens, H. D'Souza, V. Yau, C. Olcott IV, B. A. Reitz, D. C. Miller, and P. J.A. van der Starre
Plasma cefazolin levels during cardiovascular surgery: Effects of cardiopulmonary bypass and profound hypothermic circulatory arrest
J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1338 - 1343.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
B. J. Leavitt, E. K. Fellinger, and J. C. Hebert
Cefazolin prophylaxis during cardiac operations: Reply
Ann. Thorac. Surg., February 1, 2004; 77(2): 756 - 756.
[Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
J.-J. Lehot
Cefazolin prophylaxis during cardiac operations
Ann. Thorac. Surg., February 1, 2004; 77(2): 755 - 756.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2002 by The Society of Thoracic Surgeons.